- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Da Costa's syndrome.
Displaying page 1 of 1.
EudraCT Number: 2020-001175-32 | Sponsor Protocol Number: BIA-91067-404 | Start Date*: 2020-09-29 | |||||||||||
Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. | |||||||||||||
Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated pain. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) IT (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001176-15 | Sponsor Protocol Number: BIA-91067-405 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
Full Title: Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. | |||||||||||||
Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002169-21 | Sponsor Protocol Number: CP40563 | Start Date*: 2018-11-19 | ||||||||||||||||||||||||||
Sponsor Name:Roche Farma SA que realiza un el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE (OSELTAMIVIR)-CONTROLLED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS 1 T... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002154-70 | Sponsor Protocol Number: CP40559 | Start Date*: 2019-10-24 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004046-28 | Sponsor Protocol Number: AUR-VCS-2016-02 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004056-37 | Sponsor Protocol Number: MV40618 | Start Date*: 2019-10-17 | ||||||||||||||||||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY P... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Temporarily Halted) GB (GB - no longer in EU/EEA) GR (Completed) HU (Completed) PL (Completed) FR (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005830-14 | Sponsor Protocol Number: CVAY736K12301 | Start Date*: 2022-07-04 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patien... | |||||||||||||
Medical condition: Lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) EE (Ongoing) LT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004045-81 | Sponsor Protocol Number: AUR-VCS-2016-01 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Ne... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) ES (Completed) NL (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017905-13 | Sponsor Protocol Number: BO22589/TDM4788g | Start Date*: 2010-04-22 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versu... | |||||||||||||||||||||||
Medical condition: First line treatment in HER2 positive progressive or recurrent locally advanced or metastatic breast cancer (MBC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) FR (Completed) SE (Completed) DK (Completed) HU (Completed) CZ (Completed) GB (Completed) IT (Completed) BE (Completed) PT (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
